Recent Posts
Archives
Categories
-
Expedited PathwaysOctober 18th, 2016
-
What’s required to register a prescription medicine?August 28th, 2014
-
Does the benefit of the medicine outweigh the risk?August 29th, 2014
-
Expedited PathwaysOctober 18th, 2016
-
Updated TGA Guideline on the Regulation of BiosimilarsJanuary 22nd, 2016
-
Proposed Changes to Immunogenicity Requirements for Biopharmaceuticals (Part 1)November 30th, 2015
-
CMC Development of BiosimilarsNovember 26th, 2015
-
The Trans-Pacific Partnership and Biological MedicinesOctober 7th, 2015
-
Approval of Infliximab Biosimilar in AustraliaAugust 24th, 2015
-
European Guidance with regard to Biosimilar Recombinant G-CSFJuly 29th, 2015
-
Safety of biosimilar medicinesJune 19th, 2015
-
Gene TherapiesMay 30th, 2015
-
The Challenges of ImmunogenicityApril 22nd, 2015
-
Regulatory Evaluation of BiosimilarsMarch 24th, 2015
-
Shared Evaluation of Generic ApplicationsFebruary 10th, 2015
-
Global Development of BiosimilarsJanuary 27th, 2015
-
Adaptive Pathways for Drug DevelopmentDecember 23rd, 2014
-
Australia and New Zealand Therapeutics Product Agency (ANZTPA) – What Next?November 21st, 2014
-
Data exclusivityNovember 13th, 2014
-
Biotherapeutics ManufacturingOctober 21st, 2014
-
Tissue and Cell TherapiesOctober 13th, 2014
-
Cell Banks: the Foundation of Biotechnology/Biological ProductsOctober 10th, 2014
Recent Posts
Contact Info
PO Box 183 Williamstown VIC 3016 Australia
Phone: +61 3 9013 8531
Fax: +61 3 9013 8531
Recent Comments